Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-PS2
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Ad-PS2 is an investigational bivalent adenoviral-vector-based vaccine designed for the treatment of prostate cancer. Developed by researchers at the National Cancer Institute (NCI), it utilizes an adenovirus platform to deliver two key prostate-associated tumor antigens: Prostate-Specific Antigen (PSA) and Prostate-Specific Membrane Antigen (PSMA). The vaccine is engineered to stimulate a robust, antigen-specific CD8+ T-cell immune response against malignant prostate cells. Preclinical studies have demonstrated that Ad-PS2 exhibits significant therapeutic synergy when combined with immune checkpoint inhibitors, particularly CTLA-4 blockade. This combination therapy has been shown to increase intratumoral CD8+ T-cell infiltration and establish durable immune protection against tumor rechallenge, suggesting a potential strategy to overcome immunotherapy resistance in prostate cancer patients.
- Other names
- Adenovirus-based bivalent prostate cancer vaccineAd5-PSA-PSMA vaccineAd-5-PSA-PSMA vaccineAd 5-PSA-PSMA vaccine
02
Targets
PSMA (Prostate-specific membrane antigen)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on Ad-PS2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-PS2.